icon-folder.gif   Conference Reports for NATAP  
  3rd International Workshop on HIV and Aging
November 5-6, 2012
Baltimore, MD
Back grey_arrow_rt.gif
The Prevalence of a Positive Screen for Neurocognitive Impairment and Anxiety/Depression in HIV-1 Infected Patients Across Western Europe and Canada - The CRANIum Study: Age Analysis
  Reported by Jules Levin
3rd International Workshop on HIV & Aging. 5-6 November, 2012. Baltimore, MD,
Kevin Robertson1, Carmen Bayon2, Jean-Michel Molina3, John Gill4, Jose Luis Casado5, Cristina de Alvaro6, Angel Burgos6, Esther Cabrero6, Michael Norton7, Matt Guion7, Jean van Wyk8
(1)University of North Carolina, Chapel Hill, North Carolina, USA; (2) Hospital Universitario La Paz, IdiPAZ, Madrid, Spain; (3) H˘pital Saint Louis; (4) S Alberta HIV clinic, Calgary, Canada; (5) Hospital Ramon y Cajal, Madrid, Spain; (6) Abbott Laboratories, Madrid, Spain; (7) Abbott Laboratories, Chicago, Illinois; (8) Abbott Laboratories, Paris, France
from Jules: frankly I dont believe these findings, that patients >50 had more diabetes, hyperlipidemia & hypertension in this study but yet no more cognitive impairment? Still of note, 41% had NCI, cognitive impairment, 15% depression, 33% anxiety. HIV enters the nervous system, CNS, early after infection & remains there despite undetectable viral load from HAART, this might cause ongoing enduring affects on cognitive impairent, depression, anxiety & other nervous system related conditions, AND when people in general age their nervous system starts to deteriorate, so the convergence of these 2 pieces of information would suggest that when HIV+ individuals age neurologic disease would worsen. I suggest this study compares <50 vs >50, perhaps a better comparison would be to look at HIV+ >60 vs <40.
While cautioning that results must be interpreted in light of demographic and clinical differences between the two age groups, the researchers suggested their findings "support a strategy of regular screening for and clinical management of anxiety, depression and neurocognitive impairment for all HIV-infected patients."